midazolam has been researched along with Hepatitis C, Chronic in 7 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study examined the impact of chronic hepatitis C infection (CHC) on the pharmacokinetics of the cytochrome P450 3A probe midazolam in patients without significant liver disease who were either treatment naïve or prior interferon null-responders." | 9.17 | Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. ( Blotner, S; Brennan, BJ; Morcos, PN; Moreira, SA; Shulman, NS; Smith, PF, 2013) |
| "The aim of this study was to evaluate the effects of danoprevir in combination with low-dose ritonavir (danoprevir/r) and placebo plus low-dose ritonavir on the pharmacokinetics of probe drugs for cytochrome P450 (CYP) 3A and CYP2C9, in patients with chronic hepatitis C." | 9.17 | A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. ( Brennan, BJ; Chang, L; Giraudon, M; Kulkarni, R; Morcos, PN; Shulman, N; Smith, PF; Tran, JQ, 2013) |
| " This study examined the impact of chronic hepatitis C infection (CHC) on the pharmacokinetics of the cytochrome P450 3A probe midazolam in patients without significant liver disease who were either treatment naïve or prior interferon null-responders." | 5.17 | Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate. ( Blotner, S; Brennan, BJ; Morcos, PN; Moreira, SA; Shulman, NS; Smith, PF, 2013) |
| "The aim of this study was to evaluate the effects of danoprevir in combination with low-dose ritonavir (danoprevir/r) and placebo plus low-dose ritonavir on the pharmacokinetics of probe drugs for cytochrome P450 (CYP) 3A and CYP2C9, in patients with chronic hepatitis C." | 5.17 | A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail. ( Brennan, BJ; Chang, L; Giraudon, M; Kulkarni, R; Morcos, PN; Shulman, N; Smith, PF; Tran, JQ, 2013) |
| "Ritonavir is a powerful inhibitor of cytochrome P450 3A (CYP3A) that metabolizes many antiretrovirals." | 2.73 | Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. ( Greenblatt, DJ; Kaufman, RC; Knox, TA; Oleson, L; von Moltke, LL; Wanke, CA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morcos, PN | 2 |
| Moreira, SA | 1 |
| Brennan, BJ | 2 |
| Blotner, S | 1 |
| Shulman, NS | 1 |
| Smith, PF | 2 |
| Chang, L | 1 |
| Kulkarni, R | 1 |
| Giraudon, M | 1 |
| Shulman, N | 1 |
| Tran, JQ | 1 |
| Cheng, Y | 1 |
| Ma, L | 1 |
| Chang, SY | 1 |
| Humphreys, WG | 1 |
| Li, W | 1 |
| Knox, TA | 1 |
| Oleson, L | 1 |
| von Moltke, LL | 1 |
| Kaufman, RC | 1 |
| Wanke, CA | 1 |
| Greenblatt, DJ | 1 |
| Ti, L | 1 |
| Hayashi, K | 1 |
| Kaplan, K | 1 |
| Suwannawong, P | 1 |
| Wood, E | 1 |
| Montaner, J | 1 |
| Kerr, T | 1 |
| Lluch Fernández, M | 1 |
| Vallejo Uclés, A | 1 |
| Vallejo Cantarero, F | 1 |
| Zurita Castro, F | 1 |
| Huelva Ramírez, E | 1 |
| Moreno Carmona, C | 1 |
| Ferencz, S | 1 |
| Batey, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1[NCT01185860] | Phase 1 | 59 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for midazolam and Hepatitis C, Chronic
| Article | Year |
|---|---|
Influence of chronic hepatitis C infection on cytochrome P450 3A4 activity using midazolam as an in vivo probe substrate.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Female; Hepacivir | 2013 |
A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Topics: Adult; Antiviral Agents; Aryl Hydrocarbon Hydroxylases; Cyclopropanes; Cytochrome P-450 CYP2C9; Cyto | 2013 |
Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.
Topics: Administration, Oral; Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome | 2008 |
4 other studies available for midazolam and Hepatitis C, Chronic
| Article | Year |
|---|---|
Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Topics: Algorithms; Antiviral Agents; Benzazepines; Biotransformation; Carbamates; Cells, Cultured; Cytochro | 2016 |
HIV test avoidance among people who inject drugs in Thailand.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Serodiagnosis; Amphetamine-Related Disorders; Develo | 2013 |
[Anesthesia and intraoperative treatment in 2 cases of simultaneous liver, pancreas, and kidney transplantation].
Topics: Adult; Anesthesia, General; Cardiomyopathy, Hypertrophic; Diabetes Mellitus, Type 1; Diabetic Nephro | 1999 |
Can pre-emptive analgesia reduce pain experienced after liver biopsy?
Topics: Analgesia; Biopsy, Needle; Bupivacaine; Hepatitis C, Chronic; Humans; Infusions, Intravenous; Liver | 2002 |